Transmucosal methods for treating psychiatric and neurological conditions

US11052083B2 · kind B2 · utility

Assignee

• INTRA-CELLULAR THERAPIES, INC. · US

Inventors

• Peng Li · New York, US
• Wei Yao · Shanghai, CN
• Robert E. Davis · San Diego, US

Key dates

• Filing date: Jun 12, 2020
• Grant date: Jul 6, 2021
• Expiry date: Jun 12, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/38
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.